Print Friendly, PDF & Email

NCT/Study#

NCT03328078 /

CA-4948-101

An Open-Label, Dose Escalation And Dose Expansion Trial Evaluating The Safety, Pharmacokinetics, Pharmacodynamics, And Clinical Activity Of Orally Administered CA-4948 In Patients With Relapsed Or Refractory Hematologic Malignancies

DISEASE GROUP:
Lymphoma
current phase:
Phase I
STUDY STATUS:
Accepting Patients
Location:
Hackensack, NJ
For More information: